TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04309149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT fats
Description: Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
Study: NCT01195662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, Up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, once daily, Up to 12 weeks
Study: NCT04156113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo intermittent recovery test (level 1)
Description: The Yo-Yo intermittent recovery test (level 1) will be administered once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo intermittent recovery test (level 1)
Description: The Yo-Yo intermittent recovery test (level 1) will be administered once.
Study: NCT01878968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Script and CPR/Mechanical ventilation video.
Description: Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Script and CPR/Mechanical ventilation video.
Description: Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
Study: NCT04249908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.
Study: NCT01518894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.20 mg oral solution Q24 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution Q24 hours for 14 days
Study: NCT00118209

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV
Study: NCT02166619

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS + physical therapy
Description: Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + physical therapy
Description: Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy
Study: NCT04331470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Pill + Budesonide+Formoterol inhaler
Description: Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir + hydoxychloroquine
Description: Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir + hydoxychloroquine
Description: Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
Study: NCT02664506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word repetition after a time delay.
Description: This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
Study: NCT03494296

Intervention type: DRUG
Intervention: patients received D-COP regimen chemotherapy
Description: patients received D-COP regimen chemotherapy
Study: NCT01396213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatin capsule
Study: NCT01032720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
Study: NCT00617175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Defibrillator
Description: Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Defibrillator
Description: number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
Study: NCT01810003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High DHA
Description: 10 week supplementation period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High EPA
Description: 10 week supplementation period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 week supplementation period
Study: NCT01797263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Exercise
Description: A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
Study: NCT03793907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPS to Enhance Physical Activity
Description: Complete a walking program
Study: NCT01539226

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Ring
Description: Dapivirine Vaginal Ring containing 0.0 mg of dapivirine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 25 mg
Description: Dapivirine Vaginal Ring containing 25 mg of dapivirine
Study: NCT03111420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: Administration of P2Y12 inhibitor antiplatelet therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: Administration of P2Y12 inhibitor antiplatelet therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: Administration of P2Y12 inhibitor antiplatelet therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet function test
Description: Blood is drawn for testing of platelet aggregation activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet function test
Description: Blood is drawn for testing of platelet aggregation activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet function test
Description: Blood is drawn for testing of platelet aggregation activity
Study: NCT04188262

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NVS Therapy
Description: Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
Study: NCT00118209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: IV or CIVI
Study: NCT01632891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Study: NCT01742312

Intervention type: RADIATION
Intervention: DEXA scan
Description: all patients will undertake a full body DEXA scan before and after chemotherapy

Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: All patients will have a muscle biopsy before and after chemotherapy

Intervention type: OTHER
Intervention: cardio-pulmonary exercise testing (CPEX)
Description: patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
Study: NCT02063568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT00523939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine liposome injection
Description: 50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine liposome injection
Description: 50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
Study: NCT03194269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EARFOLD®
Description: EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
Study: NCT00317629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled nitric oxide releasing patch
Description: daily nitric oxide patch application during 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglumine antimoniate
Description: 20mg/kg daily during 20 days
Study: NCT03081832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Not treated.
Study: NCT02771977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-specific alert
Description: A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
Study: NCT04492982

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 1 hour of group format, guided yoga practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distress Tolerance
Description: 1 hour didactic group format, to develop distress tolerance skills
Study: NCT01030419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based, DVD-delivered physical activity
Description: Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care/Wait list
Description: Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
Study: NCT02071225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
Study: NCT03280238

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of pupil dilation and analgesia nociception index
Description: painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
Study: NCT01569295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match idelalisib
Description: Placebo to match idelalisib administered orally twice daily
Study: NCT03145415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: 1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Pudendal block
Description: 0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
Study: NCT01156545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 40mg, once a day, oral intake, every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBW 2992
Description: BIBW 2992 40mg, once a day, oral intake, every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 40mg, once a day, oral intake, every day.
Study: NCT01507311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose injected subcutaneously (under the skin)
Study: NCT03388151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
Study: NCT01387659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric emptying test
Description: Gastric emptying tests will be performed at baseline, 6 months and 12 months
Study: NCT03784638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lingually-based triangle flap design
Description: A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: buccally based triangular flap design
Description: A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
Study: NCT00826969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 320µg Ciclesonide versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02653625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 150 mg
Description: One tablet of CVC 150 mg once daily taken with food in the morning.
Study: NCT01807403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
Study: NCT02042352

Intervention type: OTHER
Intervention: pH glove
Study: NCT00485264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir poloxamer film coated tablet
Description: Final Selected Dose: 400-mg tablet taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir chewable tablet
Description: Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir chewable tablet
Description: Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir oral granules for suspension (20 mg/mL)
Description: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir oral granules for suspension (20 mg/mL)
Description: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir poloxamer film coated tablet
Description: Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
Study: NCT01295749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal tube ventilation and continuous chest compression
Description: Comparison of no flow time between two strategies in out of hospital cardiac arrest

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laryngeal tube ventilation and continuous chest compression
Description: Comparison of no flow time between two strategies in out of hospital cardiac arrest
Study: NCT01644656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI ultrasound
Description: ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures